Attitudes and Perceptions Toward Authorized Deception: A Pilot Comparison of Healthy Controls and Fibromyalgia Patients
- PMID: 31009537
- PMCID: PMC7139203
- DOI: 10.1093/pm/pnz081
Attitudes and Perceptions Toward Authorized Deception: A Pilot Comparison of Healthy Controls and Fibromyalgia Patients
Abstract
Objective: Little is known about the perceptions and attitudes of participants who volunteer in studies involving authorized deception. Thus, this cross-sectional pilot study measured, for the first time, the perceptions about participation in an authorized-deception placebo analgesia study in chronic pain patients with fibromyalgia and assessed whether their perceptions differed from healthy controls.
Methods: An anonymous survey with questions about trust in research and willingness to participate in future research involving deception was mailed to participants in both groups after completion of the parent study. Statistical analyses were performed using the Mann-Whitney U and chi-square tests (31 controls and 16 fibromyalgia patients were included in the analyses).
Results: The majority of participants expressed little or no concern about the deception, still trusted the scientific process, and found the debriefing procedure helpful and worthwhile. Group differences were found in willingness to 1) participate in the parent study had the deceptive element been disclosed in advance (controls = definitely, fibromyalgia patients = probably, U = 341.5, P = 0.01) and 2) participate in future studies (controls = definitely, fibromyalgia patients = probably, U = 373, P < 0.001).
Conclusions: Despite slightly less favorable responses of fibromyalgia patients and the relatively small size of the study, these findings suggest that attitudes and perceptions about participating in an authorized placebo study remain positive in both healthy and chronic pain populations.
Keywords: Deception; Pain; Perception; Placebo Analgesia.
© 2019 American Academy of Pain Medicine.
Similar articles
-
Inclusion of authorized deception in the informed consent process does not affect the magnitude of the placebo effect for experimentally induced pain.Pain. 2010 May;149(2):208-215. doi: 10.1016/j.pain.2009.12.004. Epub 2010 Feb 20. Pain. 2010. PMID: 20172652
-
A Comparison of Deceptive and Non-Deceptive Placebo Analgesia: Efficacy and Ethical Consequences.Ann Behav Med. 2017 Apr;51(2):307-315. doi: 10.1007/s12160-016-9854-0. Ann Behav Med. 2017. PMID: 27995547 Clinical Trial.
-
Lower Placebo Responses After Long-Term Exposure to Fibromyalgia Pain.J Pain. 2017 Jul;18(7):835-843. doi: 10.1016/j.jpain.2017.02.434. Epub 2017 Mar 7. J Pain. 2017. PMID: 28279705
-
Novel study designs to investigate the placebo response.BMC Med Res Methodol. 2011 Jun 10;11:90. doi: 10.1186/1471-2288-11-90. BMC Med Res Methodol. 2011. PMID: 21663609 Free PMC article. Review.
-
Why Are Women with Fibromyalgia so Stigmatized?Pain Med. 2020 May 1;21(5):882-888. doi: 10.1093/pm/pnz350. Pain Med. 2020. PMID: 31986200 Review.
Cited by
-
What should constitute a control condition in psychedelic drug trials?Nat Ment Health. 2024 Oct;2(10):1152-1160. doi: 10.1038/s44220-024-00321-2. Epub 2024 Sep 30. Nat Ment Health. 2024. PMID: 39781538 Free PMC article.
-
Patient and Provider Acceptability of a Patient Preauthorized Concealed Opioid Reduction.Pain Med. 2021 Jul 25;22(7):1651-1659. doi: 10.1093/pm/pnaa454. Pain Med. 2021. PMID: 33674821 Free PMC article.
-
Attitudes Toward a Pre-authorized Concealed Opioid Taper: A Qualitative Analysis of Patient and Clinician Perspectives.Front Psychiatry. 2022 Mar 24;13:820357. doi: 10.3389/fpsyt.2022.820357. eCollection 2022. Front Psychiatry. 2022. PMID: 35401245 Free PMC article.
-
Do patients with fibromyalgia syndrome and healthy people differ in their opinions on placebo effects in routine medical care?Pain Pract. 2025 Feb;25(2):e70000. doi: 10.1111/papr.70000. Pain Pract. 2025. PMID: 39868837 Free PMC article.
-
Point-of-care tools to support optometric care provision to people with age-related macular degeneration: A randomised, placebo-controlled trial.Ophthalmic Physiol Opt. 2022 Jul;42(4):814-827. doi: 10.1111/opo.12970. Epub 2022 Mar 14. Ophthalmic Physiol Opt. 2022. PMID: 35285531 Free PMC article. Clinical Trial.
References
-
- Benham B. Moral accountability and debriefing. Kennedy Inst Ethics J 2008;18(3):253–73. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical